FDA reviewers: Bronchodilation 'somewhat modest' for BI's olodaterol in COPD
This article was originally published in Scrip
While data for Boehringer Ingelheim's olodaterol showed the experimental long-acting beta-agonist (LABA) at the 5mcg dose appears to have a clinically significant effect on bronchodilation in patients with chronic obstructive pulmonary disease (COPD), US FDA drug reviewers said the magnitude of that effect is somewhat modest, which they said may be related to the baseline medications allowed in the firm's 48-week trials.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.